You are here

Article Text

Article menu
Download PDFPDF
Rare disease
CASE REPORT
Rothmund-Thomson syndrome (RTS) with osteosarcoma due to RECQL4 mutation
  1. Anas Salih1,
  2. Susumu Inoue2,3,
  3. Nkechi Onwuzurike1,3
  1. 1 Department of Combined Medicine-Pediatrics Residency Program, Hurley Medical Center, Flint, Michigan, USA
  2. 2 Department of Pediatics, Hurley Medical Center, Flint, Michigan, USA
  3. 3 Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, Flint, Michigan, USA
  1. Correspondence to Dr Susumu Inoue, sinoue1{at}hurleymc.com

Summary

Rothmund-Thomson syndrome (RTS) is a rare autosomal recessive disorder with clinical features consisting of poikiloderma, skeletal abnormalities, sparse hair, absent or scanty eyelashes and eyebrows and short stature. Patients with RTS due to genetic mutations of RECQL4 genes carry a high risk of developing osteosarcoma during childhood. Because of this, early genetic diagnosis is important. Here, we describe a 14-year-old white boy who developed an erythematous rash on both cheeks before the age of 3 months and was noted to have absent eyelashes and scanty eyebrows. He was found to have compound heterozygous mutations of the RECQL4 gene alleles at the age of 6 months and was diagnosed to have RTS type II. He subsequently developed osteosarcoma at age 10 which was successfully treated, and currently he has been tumour free for over 3 years.

  • dermatology
  • paediatric oncology
  • congenital disorders
  • genetics

https://doi.org/10.1136/bcr-2017-222384

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors AS wrote the initial manuscript draft. NO read and approved the final product. SI supervised, edited and approved the manuscript from beginning to end.

    • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.